Riferimento farmaci
Sacituzumab govitecan
Sacituzumab govitecan is a medicine in the class oncology. It is used for breast cancer.
- Classe del farmaco: Oncology
- Indicato per: breast cancer
Ultimo aggiornamento Fonti: US FDA label
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Oncology
- Codice ATC
- L01FX06
- Forme farmaceutiche comuni
- polvere
- Dosaggi comuni
- 180 mg
- Interazioni note
- 2 (Controindicata: 1 · Maggiore: 1)
- Nomi commerciali
- 2
- Paesi e mercati
- 2
Per cosa si usa
Come agisce
Trop-2-directed antibody-drug conjugate. The humanized antibody binds Trop-2-expressing cancer cells and is internalized, releasing SN-38, a topoisomerase I inhibitor. SN-38 prevents re-ligation of single strand breaks, causing DNA damage, apoptosis and cell death.
Dose abituale nell'adulto (sintesi del foglio illustrativo)
Triple-negative breast cancer or HR-positive/HER2-negative breast cancer: 10 mg/kg IV infusion on Days 1 and 8 of each 21-day cycle, as a single agent or with pembrolizumab; continue until disease progression or unacceptable toxicity; do not exceed 10 mg/kg
Gravidanza e allattamento
- Gravidanza
- Unsafe Can cause birth defects or embryo-fetal death: it contains SN-38, a genotoxic drug that targets dividing cells. No human or animal reproduction data. Check pregnancy status; use effective contraception during treatment and for 6 months after (men: 3 months).
- Allattamento
- Unsafe No human milk data. The antibody part is large and poorly absorbed, but the SN-38 payload may enter milk. US label: do not breastfeed during treatment and for 1 month after the last dose.
Effetti indesiderati segnalati
- Decreased leukocyte count
- Decreased neutrophil count
- Decreased hemoglobin
- Nausea
- Diarrhea
- Fatigue
Avvertenze in evidenza
- Can cause severe, life-threatening or fatal neutropenia. Withhold for ANC below 1500/mm3 or neutropenic fever; monitor blood counts; give primary G-CSF prophylaxis to patients at increased risk of febrile neutropenia; treat febrile neutropenia with anti-infectives without delay. Can cause severe diarrhea: monitor, give fluids and electrolytes, evaluate for infection and start loperamide; if severe, withhold until ≤ Grade 1 and reduce subsequent doses.
Controindicazioni
- Severe hypersensitivity reaction to TRODELVY.
Chi deve prestare attenzione
- Neutropenia occurred in 64% of patients (Grade 3-4 in 48%); monitor ANC and give G-CSF prophylaxis to patients at increased risk.
- Severe diarrhea; evaluate for infection and start loperamide; fluid and electrolyte replacement.
- Serious hypersensitivity and infusion-related reactions including anaphylaxis; premedicate and observe for at least 30 minutes after infusion.
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Interazioni principali (2)
- Irinotecan + Sacituzumab govitecan Contraindicated
- Sacituzumab govitecan + Siponimod Major
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Sacituzumab govitecan: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- IV preparation and dilution
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altri farmaci della stessa classe
Domande frequenti
What is Sacituzumab govitecan used for?
Sacituzumab govitecan is a medicine in the class oncology. It is used for Breast cancer.
What side effects have been reported with Sacituzumab govitecan?
Decreased leukocyte count, Decreased neutrophil count, Decreased hemoglobin, Nausea, Diarrhea, Fatigue. Serious warning: Can cause severe, life-threatening or fatal neutropenia.
Can Sacituzumab govitecan be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause birth defects or embryo-fetal death: it contains SN-38, a genotoxic drug that targets dividing cells. No human or animal reproduction data. Check pregnancy status; use effective contraception during treatment and for 6 months after (men: 3 months). Breastfeeding: Unsafe. No human milk data. The antibody part is large and poorly absorbed, but the SN-38 payload may enter milk. US label: do not breastfeed during treatment and for 1 month after the last dose.
What does Sacituzumab govitecan interact with?
MediHelp lists 2 known interactions for Sacituzumab govitecan. Contraindicated: 1 · Major: 1. The most serious include Irinotecan, Siponimod.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
